Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells

被引:11
|
作者
Sadzuka, Y
Egawa, Y
Sawanishi, H
Miyamoto, K
Sonobe, T
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Shizuoka 4228526, Japan
[2] Hokuriku Univ, Sch Pharm, Kanazawa, Ishikawa 9201181, Japan
[3] Kanazawa Univ, Dept Pharmacol & Pharmaceut, Kanazawa, Ishikawa 9200934, Japan
关键词
xanthine derivative; biochemical modulator; XT-141; doxorubicin;
D O I
10.1016/S0378-4274(02)00227-8
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
It was reported that xanthine derivatives (caffeine and 1-methyl-3-propyl-7-butylxanthine) enhanced the antitumor activity of doxorubicin (DOX) with increasing DOX concentrations in tumors in vivo in our previous papers. In addition, these actions were found to be related to the inhibitory activity toward DOX efflux from tumor cells in vitro. In this study, we searched for novel biochemical modulators of DOX among 3-n-propylxanthines with functional groups at the 1- or 7-position by using an assay system for their inhibitory effect on DOX efflux from P388 leukemia and DOX resistant P388 leukemia (P388/DOX) cells. 1-Substituted xanthines facilitated the DOX efflux from P388 cells. In contrast, among 7-substituted xanthines, XT-141 and XT-139 significantly inhibited the DOX efflux from P388 cells. In addition, XT-141 inhibited the DOX efflux from P388/DOX cells, and P-glycoprotein (P-gp) inhibitor facilitated DOX influx and inhibited DOX efflux from P388/DOX cells in a dose-dependent manner. These results indicated that the resistance of P388/DOX might depend on the over-expression of P-gp, and that XT-141 inhibited DOX efflux through its interaction with P-gp. We suspect that XT-141 is a useful biochemical modulator of DOX in DOX-resistant tumors with over-expression of P-gp in addition in DOX-sensitive tumors. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 50 条
  • [1] BIOCHEMICAL AND MORPHOLOGICAL-STUDIES IN P388 SENSITIVE AND DOXORUBICIN RESISTANT (P388 DX) LEUKEMIA-CELLS
    FACCHINETTI, T
    MALISANO, G
    SALARDI, S
    GERONI, C
    BELLINI, O
    ESPOSITO, G
    GIULIANI, FC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 343 - 343
  • [2] Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines
    Liu, QY
    Tan, BKH
    LIFE SCIENCES, 2000, 67 (10) : 1207 - 1218
  • [3] EVALUATION OF NEW ANTHRACYCLINES ON P388-LEUKEMIA SENSITIVE (P388/S) OR RESISTANT (P388/R) TO DOXORUBICIN (DX)
    GERONI, CM
    PODESTA, A
    BARBIERI, BM
    GIULIANI, FC
    CASAZZA, AM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 280 - 280
  • [4] Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia
    Colombo, T
    Paz, OG
    DIncalci, M
    BRITISH JOURNAL OF CANCER, 1996, 73 (07) : 866 - 871
  • [5] DOXORUBICIN RESISTANCE IN P388 LEUKEMIA - EVIDENCE FOR REDUCED DRUG INFLUX
    RAMU, A
    POLLARD, HB
    ROSARIO, LM
    INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (03) : 539 - 547
  • [6] INCREASED RADIATION SENSITIVITY OF P388 CELLS RESISTANT TO DOXORUBICIN (P388-ADR)
    GLAUBIGER, D
    RAMU, A
    COHEN, L
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 258 - 258
  • [7] LEUKEMIA P388-TUMORS RESISTANT TO VINCRISTINE (P388/VCR), ADRIAMYCIN (P388/ADR), OR ARABINOSYLCYTOSINE (P388/ARA-C) - CROSS-RESISTANCE (P388/VCR AND P388/ADR) AND COLLATERAL SENSITIVITY (P388/ARA-C) TO HOMOHARRINGTONINE (H) (NSC 141633)
    WILKOFF, LJ
    DULMADGE, EA
    TRADER, MW
    SCHABEL, FM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 199 - 199
  • [8] RESTORATION OF DOXORUBICIN RESPONSIVENESS IN DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS
    RAMU, A
    SPANIER, R
    RAHAMIMOFF, H
    FUKS, Z
    BRITISH JOURNAL OF CANCER, 1984, 50 (04) : 501 - 507
  • [9] THERAPEUTIC SYNERGISM (TS) OF HOMOHARRINGTONINE (H) PLUS 5-FLUOROURACIL (FU) AGAINST LEUKEMIA P388 (P388/0) AND ARA-C-RESISTANT P388 (P388/ARA-C)
    LASTER, WR
    TRADER, MW
    SCHABEL, FM
    CORBETT, TH
    GRISWOLD, DP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 199 - 199
  • [10] EFFECTS OF CYTOSINE-ARABINOSIDE ON RESISTANT P388 LEUKEMIA-CELLS
    SPRIGGS, DR
    ROBBINS, GK
    KUFE, DW
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 230 - 230